FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1601291073> ?p ?o ?g. }

• W1601291073 endingPage "5" @default.
• W1601291073 startingPage "1151" @default.
• W1601291073 abstract "Merbarone, a nonsedating derivative of thiobarbituric acid, has demonstrated excellent activity against certain murine tumors, including L1210 and P388 leukemias, B16 melanoma, and M5076 sarcoma. Preclinical studies suggested that the antitumor effects of this drug were schedule dependent, since repeated dosing increased killing of tumor cells when compared to intermittent injections. We have completed a Phase I clinical and pharmacological study of merbarone in which the drug was administered both as a 2-h infusion and as a continuous i.v. infusion over 24 h. In view of the increased toxicity observed in animals following bolus injections and the possibility of schedule-dependent anticancer activity, a schedule of drug administration daily for 5 days was selected. Fifty patients with advanced cancer were treated at dose levels that ranged from 100 to 1500 mg/m2/day. When the drug was administered by peripheral vein, phlebitis was observed at the infusion site at daily doses greater than or equal to 150 mg/m2. Therefore, all patients who received drug doses greater than or equal to 200 mg/m2 were treated by continuous i.v. infusion using central venous catheters. Renal insufficiency, initially observed at a dose of 1000 mg/m2/day, was the dose-limiting toxic reaction at 1500 mg/m2/day. Three of five patients treated at the highest dose level were unable to complete the infusion due to this effect. Marked hypouricemia was observed in all patients. Other toxic effects were mild and included nausea, fatigue, leukopenia, thrombocytopenia, and anorexia. Alopecia was noted in several patients who received doses greater than or equal to 1000 mg/m2/day. No major antitumor effects were observed. Dose-dependent, steady-state plasma concentrations of merbarone were reached within 24-48 h after beginning the continuous i.v. infusion. Elimination of drug from plasma followed a two-compartment model, with a t1/2 alpha of 4.2 h and a t1/2 beta of 15.3 h. Renal excretion of merbarone and its major metabolites accounted for less than 30% of the administered dose. We conclude that merbarone is relatively well tolerated with few constitutional symptoms. The current formulation of the drug causes phlebitis when administered by peripheral vein, and renal insufficiency is commonly observed at daily doses which exceed 1250 mg/m2. The recommended dose for extended Phase II evaluation is 1000 mg/m2/day daily for 5 days administered by central venous catheter." @default.
• W1601291073 created "2016-06-24" @default.
• W1601291073 creator A5020314758 @default.
• W1601291073 creator A5021150628 @default.
• W1601291073 creator A5025109344 @default.
• W1601291073 creator A5028693657 @default.
• W1601291073 creator A5036852179 @default.
• W1601291073 creator A5041586297 @default.
• W1601291073 creator A5049899013 @default.
• W1601291073 creator A5063963669 @default.
• W1601291073 creator A5073806438 @default.
• W1601291073 creator A5075859962 @default.
• W1601291073 creator A5087914424 @default.
• W1601291073 date "1990-02-15" @default.
• W1601291073 modified "2023-10-01" @default.
• W1601291073 title "Phase I clinical and pharmacological study of merbarone." @default.
• W1601291073 cites W1585524516 @default.
• W1601291073 cites W1666348064 @default.
• W1601291073 cites W1982880165 @default.
• W1601291073 cites W2016658536 @default.
• W1601291073 cites W2034002939 @default.
• W1601291073 cites W2049025695 @default.
• W1601291073 cites W2090050801 @default.
• W1601291073 cites W2416731873 @default.
• W1601291073 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2297763" @default.
• W1601291073 hasPublicationYear "1990" @default.
• W1601291073 type Work @default.
• W1601291073 sameAs 1601291073 @default.
• W1601291073 citedByCount "5" @default.
• W1601291073 countsByYear W16012910732013 @default.
• W1601291073 crossrefType "journal-article" @default.
• W1601291073 hasAuthorship W1601291073A5020314758 @default.
• W1601291073 hasAuthorship W1601291073A5021150628 @default.
• W1601291073 hasAuthorship W1601291073A5025109344 @default.
• W1601291073 hasAuthorship W1601291073A5028693657 @default.
• W1601291073 hasAuthorship W1601291073A5036852179 @default.
• W1601291073 hasAuthorship W1601291073A5041586297 @default.
• W1601291073 hasAuthorship W1601291073A5049899013 @default.
• W1601291073 hasAuthorship W1601291073A5063963669 @default.
• W1601291073 hasAuthorship W1601291073A5073806438 @default.
• W1601291073 hasAuthorship W1601291073A5075859962 @default.
• W1601291073 hasAuthorship W1601291073A5087914424 @default.
• W1601291073 hasConcept C126322002 @default.
• W1601291073 hasConcept C2777288759 @default.
• W1601291073 hasConcept C2780035454 @default.
• W1601291073 hasConcept C2780580376 @default.
• W1601291073 hasConcept C2780873365 @default.
• W1601291073 hasConcept C29730261 @default.
• W1601291073 hasConcept C43376680 @default.
• W1601291073 hasConcept C71924100 @default.
• W1601291073 hasConcept C90924648 @default.
• W1601291073 hasConcept C98274493 @default.
• W1601291073 hasConceptScore W1601291073C126322002 @default.
• W1601291073 hasConceptScore W1601291073C2777288759 @default.
• W1601291073 hasConceptScore W1601291073C2780035454 @default.
• W1601291073 hasConceptScore W1601291073C2780580376 @default.
• W1601291073 hasConceptScore W1601291073C2780873365 @default.
• W1601291073 hasConceptScore W1601291073C29730261 @default.
• W1601291073 hasConceptScore W1601291073C43376680 @default.
• W1601291073 hasConceptScore W1601291073C71924100 @default.
• W1601291073 hasConceptScore W1601291073C90924648 @default.
• W1601291073 hasConceptScore W1601291073C98274493 @default.
• W1601291073 hasIssue "4" @default.
• W1601291073 hasLocation W16012910731 @default.
• W1601291073 hasOpenAccess W1601291073 @default.
• W1601291073 hasPrimaryLocation W16012910731 @default.
• W1601291073 hasRelatedWork W141775729 @default.
• W1601291073 hasRelatedWork W1964475156 @default.
• W1601291073 hasRelatedWork W2051036097 @default.
• W1601291073 hasRelatedWork W2062650038 @default.
• W1601291073 hasRelatedWork W2079580408 @default.
• W1601291073 hasRelatedWork W2350025932 @default.
• W1601291073 hasRelatedWork W2397868246 @default.
• W1601291073 hasRelatedWork W2398830679 @default.
• W1601291073 hasRelatedWork W2468000090 @default.
• W1601291073 hasRelatedWork W2472155679 @default.
• W1601291073 hasVolume "50" @default.
• W1601291073 isParatext "false" @default.
• W1601291073 isRetracted "false" @default.
• W1601291073 magId "1601291073" @default.
• W1601291073 workType "article" @default.